Compare LKFN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | DRTS |
|---|---|---|
| Founded | 1872 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2009 | 2021 |
| Metric | LKFN | DRTS |
|---|---|---|
| Price | $61.44 | $13.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $66.00 | $17.80 |
| AVG Volume (30 Days) | 225.3K | ★ 471.5K |
| Earning Date | 10-26-2026 | 11-19-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.31 | N/A |
| Revenue | ★ $985,000.00 | N/A |
| Revenue This Year | $6.70 | N/A |
| Revenue Next Year | $5.38 | $1,235.59 |
| P/E Ratio | $19.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $54.36 | $3.43 |
| 52 Week High | $64.55 | $15.79 |
| Indicator | LKFN | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 54.48 |
| Support Level | $58.59 | $13.73 |
| Resistance Level | $64.14 | $15.23 |
| Average True Range (ATR) | 1.43 | 0.66 |
| MACD | 0.46 | 0.10 |
| Stochastic Oscillator | 84.77 | 92.31 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.